NCT05703659 is a NA clinical trial of B. longum subsp. infantis in Transmission, sponsored by University of Florida.

Who is sponsoring NCT05703659?

NCT05703659 is sponsored by University of Florida.

What drugs are being tested in NCT05703659?

Interventions in NCT05703659: B. longum subsp. infantis, L. reuteri probiotic.

What condition does NCT05703659 study?

NCT05703659 studies Transmission.

Is NCT05703659 still recruiting?

NCT05703659 is currently terminated. Last updated 1 August 2025.

Last reviewed 2025-08-01 · How we verify

NCT05703659

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Baby 2 Baby Beneficial Bacteria

Terminated NA Last updated 1 August 2025

What this trial tests

NA trial testing B. longum subsp. infantis in Transmission in 10 participants. Terminated before completion.

Timeline

1 March 2023

Primary endpoint
29 October 2024

9 April 2025

Quick facts

Lead sponsor	University of Florida
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	10
Start date	1 March 2023
Primary completion	29 October 2024
Estimated completion	9 April 2025
Sites	1 location across United States

Drugs / interventions tested

B. longum subsp. infantis
L. reuteri probiotic

Conditions studied

Transmission — all drugs for Transmission →

Sponsor

University of Florida

Who can join

Adults 18 to 62, any sex, with Transmission. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will recruit mother-infant dyads to attend weekly lactation support groups and randomize infants to receive either an HMO consuming or non-HMO consuming probiotic. The investigators will collect infant stool before and after support group attendance. The investigators will use qPCR and metagenomic sequencing to test if the study probiotics or other bacteria transmit between infants. The investigators anticipate HMO consuming bacteria will and non-HMO consuming bacteria will not transmit between infants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05703659 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 1 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05703659.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing